文献速递泌尿男性生殖肿瘤

根治性前列腺切除术后辅助放疗对比早期挽救放疗:TROG 08.03/ANZUP RAVES 随机对照三期非劣效试验

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

BACKGROUND: Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Early salvage radiotherapy could result in similar biochemical control with lower treatment toxicity.…

要点

  • 挽救放疗未达到预设的非劣效性标准,但两组5年无生化进展率相近。
  • 挽救放疗使约半数患者免于盆腔放疗,且2级及以上泌尿生殖毒性显著更低。
  • 两组均采用64 Gy/32次前列腺床放疗,未联合雄激素剥夺治疗。

核心结论

  • 挽救放疗未满足试验预设的非劣效性标准,但生化控制与辅助放疗相似,且可让约半数男性免于盆腔放疗并显著降低泌尿生殖毒性。

研究设计与样本

  • 三期随机对照非劣效试验,在澳大利亚和新西兰32个肿瘤中心开展,共随机333例患者(辅助放疗组166例,挽救放疗组167例)。
  • 两组放疗均为前列腺床64 Gy/32次,不联合雄激素剥夺治疗,治疗前实时审核所有病例的计划质量。

主要发现

  • 2级及以上泌尿生殖毒性挽救放疗组为90/167(54%),低于辅助放疗组的116/166(70%)。
  • 2级及以上胃肠道毒性挽救放疗组为16/167(10%),辅助放疗组为24/166(14%),两组相似。

关键数值与推荐

  • 5年无生化进展率:辅助放疗86%(95%CI 81-92),挽救放疗87%(95%CI 82-93)。
  • 2级及以上泌尿生殖毒性:挽救放疗54%(90/167) vs 辅助放疗70%(116/166);2级及以上胃肠道毒性:10%(16/167) vs 14%(24/166)。

临床怎么用

  • 采用挽救放疗策略可使约半数患者避免不必要的盆腔放疗。
  • 放疗方案为前列腺床64 Gy/32次,不联合雄激素剥夺治疗,治疗前应实时审核计划质量。

局限性

  • 因事件率意外偏低而提前终止入组,实际样本量小于原计划,可能影响非劣效性检验的统计效能。
  • 治疗分配对个体随机化未设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Early salvage radiotherapy could result in similar biochemical control with lower treatment toxicity. We aimed to compare biochemical progression between patients given adjuvant radiotherapy and those given salvage radiotherapy. METHODS: We did a phase 3, randomised, controlled, non-inferiority trial across 32 oncology centres in Australia and New Zealand. Eligible patients were aged at least 18 years and had undergone a radical prostatectomy for adenocarcinoma of the prostate with pathological staging showing high-risk features defined as positive surgical margins, extraprostatic extension, or seminal vesicle invasion; had an Eastern Cooperative Oncology Group performance status of 0-1, and had a postoperative prostate-specific antigen (PSA) concentration of 0·10 ng/mL or less. Patients were randomly assigned (1:1) using a minimisation technique via an internet-based, independently generated allocation to either adjuvant radiotherapy within 6 months of radical prostatectomy or early salvage radiotherapy triggered by a PSA of 0·20 ng/mL or more. Allocation sequence was concealed from investigators and patients, but treatment assignment for individual randomisations was not masked. Patients were stratified by radiotherapy centre, preoperative PSA, Gleason score, surgical margin status, and seminal vesicle invasion status. Radiotherapy in both groups was 64 Gy in 32 fractions to the prostate bed without androgen deprivation therapy with real-time review of plan quality on all cases before treatment. The primary endpoint was freedom from biochemical progression. Salvage radiotherapy would be deemed non-inferior to adjuvant radiotherapy if freedom from biochemical progression at 5 years was within 10% of that for adjuvant radiotherapy with a hazard ratio (HR) for salvage radiotherapy versus adjuvant radiotherapy of 1·48. The primary analysis was done on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, NCT00860652. FINDINGS: Between March 27, 2009, and Dec 31, 2015, 333 patients were randomly assigned (166 to adjuvant radiotherapy; 167 to salvage radiotherapy). Median follow-up was 6·1 years (IQR 4·3-7·5). An independent data monitoring committee recommended premature closure of enrolment because of unexpectedly low event rates. 84 (50%) patients in the salvage radiotherapy group had radiotherapy triggered by a PSA of 0·20 ng/mL or more. 5-year freedom from biochemical progression was 86% (95% CI 81-92) in the adjuvant radiotherapy group versus 87% (82-93) in the salvage radiotherapy group (stratified HR 1·12, 95% CI 0·65-1·90; pnon-inferiority=0·15). The grade 2 or worse genitourinary toxicity rate was lower in the salvage radiotherapy group (90 [54%] of 167) than in the adjuvant radiotherapy group (116 [70%] of 166). The grade 2 or worse gastrointestinal toxicity rate was similar between the salvage radiotherapy group (16 [10%]) and the adjuvant radiotherapy group (24 [14%]). INTERPRETATION: Salvage radiotherapy did not meet trial specified criteria for non-inferiority. However, these data support the use of salvage radiotherapy as it results in similar biochemical control to adjuvant radiotherapy, spares around half of men from pelvic radiation, and is associated with significantly lower genitourinary toxicity. FUNDING: New Zealand Health Research Council, Australian National Health Medical Research Council, Cancer Council Victoria, Cancer Council NSW, Auckland Hospital Charitable Trust, Trans-Tasman Radiation Oncology Group Seed Funding, Cancer Research Trust New Zealand, Royal Australian and New Zealand College of Radiologists, Cancer Institute NSW, Prostate Cancer Foundation Australia, and Cancer Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020. PMID: 33002437. doi:10.1016/S1470-2045(20)30456-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。